The Top 60: Cambridge BioMarketing

Share this article:
Cambridge BioMarketing posted strong gains in 2007, notably securing AOR status for Alexion Pharmaceuticals' first product, Soliris. The agency is integrating disease awareness and product campaigns, both print and digital, for the product. Additional account wins include Vertex Pharmaceuticals' lead hepatitis C virus compound telaprevir, as well as market development and promotion assignments for Medtronic Diabetes. All in all, the agency's 50-plus staff received seven digital media development assignments in 2007, and the goal of breaking the $10 million income level is in sight for 2008.

Obstacles for the agency include, as CEO Steve West puts it, “the time-honored challenge of adding people to handle the surge and keeping product and service excellence up without killing people.” The challenge of recruiting talented staff is magnified by the agency's Boston location, says West. 
Continuous new business opportunities promise continued growth for 2008. The agency's tagline “Be Heard” could be interpreted as a response to the stormy relationship between the industry and public trust. “The industry created empowered consumers through DTC/DTP promotion, and enabled dialogue between doctors and patients. Now, those newly empowered consumers are asking direct questions to the industry and, with rare exception, not getting direct answers. Genuineness engenders trust.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.